18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
NCT ID: NCT06655545
Last Updated: 2025-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
473 participants
OBSERVATIONAL
2023-07-15
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FES PET/CT's Additional Clinical Value in ER+ BC
NCT04006626
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
NCT04992156
Characterizing Breast Cancer With 18F-FES PET/CT
NCT05613270
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer
NCT03768479
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
NCT06344767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FES-guided CDK4/6 inhibitor plus endocrine therapy cohort
The group guided with FES-PET using a CDK4/6 inhibitor plus ET.
No interventions assigned to this group
FES-guided chemotherapy cohort
The group guided with FES-PET using chemotherapy.
No interventions assigned to this group
Non-FES-guided CDK4/6 inhibitor plus endocrine therapy cohort
The group examined without FES-PET using a CDK4/6 inhibitor plus ET.
No interventions assigned to this group
Non-FES-guided chemotherapy cohort
The group examined without FES-PET using chemotherapy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who were diagnosed as HR Positive, HER2 Negative recurrent unresectable (local or regional) or stage IV (M1) breast cancer between January 2020 to February 2024;
3. Received CDK4/6 inhibitor plus endocrine treatment or chemotherapy as first-line therapy for at least one cycle;
4. Complete medical history was available.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Biyun Wang, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Biyun Wang, professor
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YOUNGBC-31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.